Construction of a Recombinant Phage-vaccine Capable of Reducing the Growth Rate of an Established LL2 Tumor Model.

In conclusion, EM-L2 displaying phage particles could be deemed as an encouraging strategy in contemporary cancer immunotherapy.
PMID: 29908541 [PubMed - in process]

Source: Iranian Journal of Allergy, Asthma and Immunology - June 1, 2018 Category: Allergy & Immunology Authors: Asadi-Ghalehni M, Rasaee MJ, Namvar Asl N, Khosravani M, Rajabibazl M, Khalili S, Modjtahedi H, Sadroddiny E Tags: Iran J Allergy Asthma Immunol Source Type: research